Drug Search Results
More Filters [+]

CV-0701

Alternative Names: CV-0701, CV 0701, CV0701
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Bivalent candidate, CV0701, encodes the spike protein of the omicron BA.4-5 variant as well as the original SARS-CoV-2 strain. (Sourced from: https://www.curevac.com/en/curevac-announces-dosing-of-first-participant-in-phase-2-study-of-modified-covid-19-mrna-vaccine-candidates-developed-in-collaboration-with-gsk/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CV-0701

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT05960097

P2

Completed

COVID-19

2024-08-30

Recent News Events